Health Care [ 8/12 ] | Health Care Equipment & Supplies [ 51/74 ]
NYSE | Common Stock
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally.
It operates through two segments: Prevention and Recovery, and Reconstructive segments.
The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.
Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools.
It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
It distributes its products through independent distributors and directly under the ESAB and DJO brands.
The company was formerly known as Colfax Corporation.
Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 25 | 0.81 Increased by +62.00% | 0.74 Increased by +8.90% |
| Feb 20, 25 | 0.98 Increased by +24.05% | 0.92 Increased by +7.02% |
| Nov 6, 24 | 0.73 Increased by +30.36% | 0.62 Increased by +17.74% |
| Aug 7, 24 | 0.62 Increased by +1.64% | 0.59 Increased by +5.08% |
| May 2, 24 | 0.50 Increased by +13.64% | 0.48 Increased by +4.17% |
| Feb 22, 24 | 0.79 Increased by +9.72% | 0.74 Increased by +6.76% |
| Nov 7, 23 | 0.56 Decreased by -5.08% | 0.54 Increased by +3.70% |
| Aug 3, 23 | 0.61 Increased by +3.39% | 0.52 Increased by +17.31% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 558.83 M Increased by +8.25% | -55.97 M Increased by +22.27% | Decreased by -10.01% Increased by +28.19% |
| Dec 31, 24 | 560.98 M Increased by +23.29% | -703.34 M Decreased by -23.83 K% | Decreased by -125.38% Decreased by -19.35 K% |
| Sep 30, 24 | 505.22 M Increased by +21.00% | -31.52 M Decreased by -994.48% | Decreased by -6.24% Decreased by -804.50% |
| Jun 30, 24 | 525.16 M Increased by +22.56% | -18.64 M Decreased by -86.47% | Decreased by -3.55% Decreased by -52.15% |
| Mar 31, 24 | 516.27 M Increased by +27.11% | -72.00 M Decreased by -215.14% | Decreased by -13.95% Decreased by -147.93% |
| Dec 31, 23 | 455.02 M Increased by +11.33% | 2.96 M Increased by +105.41% | Increased by +0.65% Increased by +104.86% |
| Sep 30, 23 | 417.52 M Increased by +8.78% | -2.88 M Increased by +95.68% | Decreased by -0.69% Increased by +96.03% |
| Jun 30, 23 | 428.50 M Increased by +8.45% | -9.99 M Decreased by -108.28% | Decreased by -2.33% Decreased by -107.64% |